GSK has reported promising clinical data for its investigational B7-H4-targeted antibody–drug conjugate (ADC), mocertatug rezetecan (also known as GSK5733584), in patients with gynaecological cancers, including ovarian and endometrial malignancies. These cancers often present at advanced stages and are associated with poor prognosis, particularly in patients who develop resistance to standard therapies such as platinum-based chemotherapy. The emergence of targeted therapies like ADCs represents a significant advancement in addressing these unmet clinical needs.

The emergence of oral glucagon-like peptide-1 (GLP-1) receptor agonists marks a significant advancement in obesity pharmacotherapy, offering needle-free alternatives to injectable agents. In this context, a new population-adjusted indirect treatment comparison (ITC), to be presented at the Obesity Medicine Association (OMA) 2026 annual meeting, evaluated the relative efficacy and tolerability of oral semaglutide 25 mg (Wegovy® pill) versus orforglipron 36 mg.